<DOC>
	<DOCNO>NCT00794781</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) , safety , tolerability , pharmacokinetics , pharmacodynamics preliminary anti-tumor activity E6201 subject advanced solid tumor .</brief_summary>
	<brief_title>A Phase 1 , Multicenter , Open-Label , Dose-Escalation , Safety , Pharmacokinetic , Pharmacodynamic Study E6201 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects must meet follow criterion eligible participate study : 1 . Willing able comply protocol provide write informed consent . 2 . Age great equal 18 year . 3 . Histologically and/or cytologically confirm metastatic melanoma progress treatment approve therapy standard effective therapy available . CNS metastases primary melanoma allow . 4 . Subjects must melanoma tumor status establish BRAFgene analysis report CLIA qualify laboratory . 5 . Subjects must least one tumor lesion accessible biopsy addition one accurately serially measurable accord RECIST 1.0 use either CT/MRI photography ( appropriate ) , measure great 1.5 cm long diameter nonlymph node great 2.0 cm short axis diameter lymph node . 6 . Female subject childbearing potential must agree use medically acceptable method contraception , abstinence , doublebarrier method ( e.g. , condom spermicide ; condom , diaphragm , spermicide ) , intrauterine device ( IUD ) , vasectomise partner . Female subject use hormonal contraceptive must also use additional approve method contraception ( describe previously ) . Contraceptive measure must start either prior Screening continue throughout entire study period 2 month last dose drug administer . Pregnant and/or lactate female exclude . 7 . Male subject must agree use contraceptive method abstinence , doublebarrier method ( e.g. , condom spermicide ; condom , diaphragm , spermicide ) . Contraceptive measure must start either prior Screening continue throughout entire study period 2 month last dose study drug administer . 8 . Adequate bone marrow function define : Absolute neutrophil count ( ANC ) great equal 1.5 x 10^9/L Hemoglobin great equal 9.0 g/dL ; however , hemoglobin value le 9.0 g/dL acceptable correct great equal 9.0 g/dL growth factor transfusion start treatment Platelet count great equal 100 x 10^9/L . 9 . Adequate renal function define : Serum creatinine le 1.5 mg/dL calculate creatinine clearance great 50 mL/minute per CockcroftGault formula 10 Adequate liver function define : Total Bilirubin within normal limit Alkaline phosphatase ( AP ) , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) less equal 2.5 x upper limit normal ( ULN ) AP , ALT , AST le equal 5 x ULN case liver metastasis liverspecific AP le equal 3 x ULN case bone metastases 11 Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 1 . 12 . Life expectancy great 3 month . Subjects meet follow criterion eligible participate study : 1 . Known human immunodeficiency virus ( HIV ) , clinical evidence active viral hepatitis B C , severe/uncontrolled infection intercurrent illness unrelated tumor . 2 . Prior surgery , radiotherapy , chemotherapy , biologic therapy , investigational agent within 4 week prior first infusion prior immunotherapy , hormonal , moleculartargeted therapy within 2 week prior first infusion . All acute toxicity relate prior treatment resolve . 3 . Active malignancy present diagnosis within past 24 month ( except treat nonmelanoma skin cancer carcinoma situ cervix ) . 4 . QT interval correct rate ( QTc ) great 450 msec electrocardiogram ( ECG ) obtain Screening ( Day 21 0 ) use Fridericia method QTc analysis . 5 . History substance alcohol abuse , opinion investigator , would prohibit participation study . 6 . History clinically significant cardiac impairment , congestive heart failure , New York Heart Association ( NYHA ) cardiac disease classification Class II , unstable angina , myocardial infarction previous 6 month , serious cardiac arrhythmia . 7 . Current significant comorbid disease , opinion investigator , would exclude subject study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>solid tumor</keyword>
</DOC>